Eugene Schneider Ionis Pharmaceuticals Inc (IONS) insider trading activity

Eugene Schneider is EVP, Chf Clinical Develop Ofcr of IONIS PHARMACEUTICALS INC. Currently has a direct ownership of 58,508 shares of IONS, which is worth approximately $2.03 Million. The most recent transaction as insider was on Jan 16, 2025, when has been sold 6,523 shares (Common Stock) at a price of $32.79 per share, resulting in proceeds of $213,889. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 58.5K

17.46% 3M change

22.27% 12M change

Total Value Held $2.03 Million

Eugene Schneider Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 16 2025	SELL Open market or private sale	$213,889 $32.79 p/Share	6,523 Reduced 10.03%	58,508 Common Stock
Jan 15 2025	BUY Exercise of conversion of derivative security	-	17,372 Added 21.08%	65,031 Common Stock
Feb 02 2024	SELL Open market or private sale	$102,700 $49.59 p/Share	2,071 Reduced 3.99%	49,812 Common Stock
Feb 01 2024	BUY Grant, award, or other acquisition	-	4,033 Added 7.21%	51,883 Common Stock
Jan 17 2024	SELL Open market or private sale	$276,402 $50.42 p/Share	5,482 Reduced 10.28%	47,850 Common Stock
Jan 16 2024	BUY Exercise of conversion of derivative security	-	15,162 Added 22.14%	53,332 Common Stock
Jan 12 2024	SELL Open market or private sale	$428,000 $53.5 p/Share	8,000 Reduced 17.33%	38,170 Common Stock
Jan 12 2024	BUY Exercise of conversion of derivative security	$260,800 $32.6 p/Share	8,000 Added 14.77%	46,170 Common Stock
Dec 26 2023	SELL Open market or private sale	$1,286,500 $51.46 p/Share	25,000 Reduced 40.95%	36,052 Common Stock
Dec 26 2023	BUY Exercise of conversion of derivative security	$1,183,500 $47.34 p/Share	25,000 Added 29.05%	61,052 Common Stock
Feb 06 2023	SELL Open market or private sale	$57,466 $40.67 p/Share	1,413 Reduced 5.36%	24,946 Common Stock
Feb 03 2023	BUY Grant, award, or other acquisition	-	4,033 Added 13.27%	26,359 Common Stock
Jan 18 2023	SELL Open market or private sale	$188,036 $39.57 p/Share	4,752 Reduced 17.55%	22,326 Common Stock
Jan 17 2023	BUY Exercise of conversion of derivative security	-	13,046 Added 32.51%	27,078 Common Stock
Oct 17 2022	SELL Payment of exercise price or tax liability	$6,699 $46.52 p/Share	144 Reduced 1.02%	14,032 Common Stock
Oct 17 2022	BUY Exercise of conversion of derivative security	-	416 Added 2.85%	14,176 Common Stock
Jan 18 2022	SELL Payment of exercise price or tax liability	$114,908 $30.12 p/Share	3,815 Reduced 21.71%	13,760 Common Stock
Jan 18 2022	BUY Exercise of conversion of derivative security	-	10,400 Added 37.18%	17,575 Common Stock
Oct 15 2021	SELL Payment of exercise price or tax liability	$5,089 $35.1 p/Share	145 Reduced 1.98%	7,175 Common Stock
Oct 15 2021	BUY Exercise of conversion of derivative security	-	417 Added 5.39%	7,320 Common Stock
Jan 15 2021	SELL Payment of exercise price or tax liability	$166,559 $61.28 p/Share	2,718 Reduced 28.25%	6,903 Common Stock
Jan 15 2021	BUY Exercise of conversion of derivative security	-	7,503 Added 43.82%	9,621 Common Stock

Eugene Schneider

EVP, Chf Clinical Develop Ofcr

Carlsbad, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells IONS shares.

Notify only if

Value

Insider Trading

Get notified when an Ionis Pharmaceuticals Inc insider buys or sells IONS shares.

Notify only if

Operation

Value

Type

News

Receive news related to IONIS PHARMACEUTICALS INC

Track Activities on IONS

Account